Masako Tomoyasu

Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice

Masaharu Nagashima, Takuya Watanabe, Michishige Terasaki et al. · Diabetologia · 2011 · 250 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin

Toshiyuki Hayashi, Tomoyasu Fukui, Noriko Nakanishi et al. · Cardiovascular Diabetology · 2017 · 200 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice

Michishige Terasaki, Masaharu Nagashima, Kyoko Nohtomi et al. · PLoS ONE · 2013 · 72 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Improvements of ambient hyperglycemia and glycemic variability are associated with reduction in oxidative stress for patients with type 2 diabetes

Makoto Ohara, Hiroe Nagaike, Satoshi Goto et al. · Diabetes Research and Clinical Practice · 2018 · 55 citations · Full text

Medicine, Biochemistry, Diabetology +16

Suppressive Effects of Glucose-Dependent Insulinotropic Polypeptide on Cardiac Hypertrophy and Fibrosis in Angiotensin II-Infused Mouse Models

Munenori Hiromura, Yusaku Mori, Kyoko Kohashi et al. · Circulation Journal · 2016 · 49 citations · Full text

Life Sciences, Cardiology, Physiology +14